Advertisement

Topics

Companies Related to "Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension" [Most Relevant Company Matches] RSS

15:53 EST 15th February 2019 | BioPortfolio

Here are the most relevant search results for "Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension" found in our extensive corporate database of over 50,000 company records.

Showing "Monotherapy Versus Dual Therapy Initial Treatment Hypertension" Companies 1–25 of 4,500+

Relevant

Ablative Solutions, Inc.

Ablative Solutions, Inc., based in Kalamazoo, Michigan, and San Jose, California, was founded in 2011 with a vision to address the unmet need of hypertension. Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea.1, 2 The ...


Pulmonary Hypertension Association (PHA)

Headquartered in Silver Spring, Md., PHA is the country’s leading organization connecting pulmonary hypertension patients, families, and medical professionals. Its mission is to find ways to prevent and cure pulmonary hypertension and provide hope for the community through support, education, advocacy and awareness. PHA provides free access to informa...

InterCure Ltd.

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug thera...


Cyberonics Sorin

Cyberonics, Inc. is a medical device company with core expertise in neuromodulation. The company developed and markets the VNS Therapy® System, which is FDA-approved for the treatment of medically refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the...

Myogen, Inc.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, ...

Xstrahl

Xstrahl is a leading designer and manufacturer of X-ray systems for use in cancer and dermatology treatments and radiation biology research, providing complete solutions for all X-ray therapy and research applications. Xstrahl has more than 15 years’ experience supporting the X-ray therapy requirements of healthcare providers around the world, from in...

MedAutonomic

MedAutonomic is a privately held medtech company dedicated to developing a bioelectric medicine to treat patients with functional diseases of the metabolic syndrome such as type-2 diabetes, hypertension and gastroesophageal reflux disease (GERD). MedAutonomic’s approach is to offer a nonsurgical alternative treatment of functional diseases with a lowe...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...

Radiation Therapy Services, Inc.

Radiation Therapy Services, Inc. is a leading developer and operator of radiation therapy centers. These centers, which are freestanding and hospital based, provide a full spectrum of radiation therapy services to cancer patients, including conventional external beam radiation treatments as well as advanced services such as prostate seed implants (brachyth...

Actelion Pharmaceuticals US, Inc.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in ...

Neurologix

Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") is a new and particularly exciting target for gene therapy because its unique properties prevent the successful treatment of many neurological disorders by conventional means such as drug therapy and s...

A&G Pharmaceutical Incorporated

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division. Pharmaceutical Division Breast cancer is the most ...

Tenax Therapeutics, Inc. 

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan and is...

Collateral Therapeutics Incorporated

Collateral's initial non-surgical gene therapy products under investigation are designed to promote and enhance angiogenesis, a natural biological process which results in the growth of additional blood vessels, to increase levels of blood flow to oxygen-deprived tissues. The Company's angiogenic products are administered using methods of gene therapy based on non-surgical adenoviral vector delive...

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials with REOLYSIN® in Canada and the U.K. and is currently conducting four Phase I or Phase I/II REOLYSIN® trials in the U.K. and the U.S. The company also has permission to commence a Phase II combina...

U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. (NASDAQ:USPH) operates 369 clinics in 43 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, non-surgical treatment of osteoarthritis, treatment for neurologically-related injuries and rehabilitation of injured work...

Texas Center for Proton Therapy

Texas Center for Proton Therapy is the North Texas region’s first proton therapy center. The center features latest-generation technology, including pencil-beam scanning and image-guided proton therapy, providing precise radiation treatment with the opportunity to reduce side effects. Opening in late 2015, the facility will provide advanced cancer tre...

Cyberonics Incorporated

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, Cyberonics has emerged as a leader in the neuromodulation industry. The VNS Therapy System uses a surgically implanted medical device that delivers elec...

Bellingham Regional Breast Center

The Bellingham Regional Breast Center provides comprehensive diagnosis and treatment for all breast disorders. Services include early diagnosis; risk analysis with genetic counseling and testing; treatment with surgery, radiation therapy, chemotherapy, endocrine therapy, targeted therapies, and immune therapy; and supportive care including counseling, phys...

EYE TECH CARE SA

EYE TECH CARE SA develops and markets non-invasive therapeutic medical devices for ophthalmology. EyeOP1® is the company's first commercial medical device for the treatment of glaucoma, a degenerative disease of the optic nerve associated with raised intraocular pressure (IOP), which mainly affects people aged over 45. Glaucoma and ocular hypertension a...

Timberline Knolls Residential Treatment Center

Timberline Knolls is a leading private residential treatment center for eating disorders and substance abuse, with or without trauma, a dual diagnosis or cooccurring disorder. Expert treatment staff offers a nurturing environment of recovery for women and girls (ages 12 and older) on a wooded 43-acre campus in suburban Chicago. Women and families seeking Christian treatment have the option of work...

U.S. Physical Therapy, Inc.          

Founded in 1990, U.S. Physical Therapy, Inc. operates 418 clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, non-surgical treatment of osteoarthritis, treatment for neurologically-related injuries and rehabilitation of injured workers. In additi...

Incara Pharmaceuticals

Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. The company currently has programs in three areas: liver cell therapy and progenitor cell therapy as a treatment for liver failure; small molecule catalytic antioxidants as treatment for stroke and tissue damage; and deligioparin (formerly named OP2000), an ultra-low molecular wei...

Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes™. The San Diego-based company’s proprietary Cargocyte™ platform are cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf ...

Bioenvision

We are a product-oriented biopharmaceutical company primarily focused upon the acquisition, development and marketing of compounds and technologies for the treatment of cancer, autoimmune disease and infection. Our product pipeline includes Evoltra® (Clofarabine), Modrenal® (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-meno...


More From BioPortfolio on "Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks